Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1067596.RAuccN5iKfB4Q_VggImjU-sC8Iu4aJmgtD2z9M1YYr_RI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1067596.RAuccN5iKfB4Q_VggImjU-sC8Iu4aJmgtD2z9M1YYr_RI130_assertion type Assertion NP1067596.RAuccN5iKfB4Q_VggImjU-sC8Iu4aJmgtD2z9M1YYr_RI130_head.
- NP1067596.RAuccN5iKfB4Q_VggImjU-sC8Iu4aJmgtD2z9M1YYr_RI130_assertion description "[They detected intense immunoreactivity for TTR at high dilutions of primary antiserum in the neoplastic epithelium of all of nine primary CP tumors (six papillomas and three carcinomas), but not in eight cellular or three papillary intracerebral ependymomas, meningiomas, oligodendrogliomas, astrocytomas, primary extracerebral papillary carcinomas (three thyroid, two breast) or five of six cerebral metastases from systemic papillary carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1067596.RAuccN5iKfB4Q_VggImjU-sC8Iu4aJmgtD2z9M1YYr_RI130_provenance.
- NP1067596.RAuccN5iKfB4Q_VggImjU-sC8Iu4aJmgtD2z9M1YYr_RI130_assertion evidence source_evidence_literature NP1067596.RAuccN5iKfB4Q_VggImjU-sC8Iu4aJmgtD2z9M1YYr_RI130_provenance.
- NP1067596.RAuccN5iKfB4Q_VggImjU-sC8Iu4aJmgtD2z9M1YYr_RI130_assertion SIO_000772 2356863 NP1067596.RAuccN5iKfB4Q_VggImjU-sC8Iu4aJmgtD2z9M1YYr_RI130_provenance.
- NP1067596.RAuccN5iKfB4Q_VggImjU-sC8Iu4aJmgtD2z9M1YYr_RI130_assertion wasDerivedFrom befree-2016 NP1067596.RAuccN5iKfB4Q_VggImjU-sC8Iu4aJmgtD2z9M1YYr_RI130_provenance.
- NP1067596.RAuccN5iKfB4Q_VggImjU-sC8Iu4aJmgtD2z9M1YYr_RI130_assertion wasGeneratedBy ECO_0000203 NP1067596.RAuccN5iKfB4Q_VggImjU-sC8Iu4aJmgtD2z9M1YYr_RI130_provenance.